-
公开(公告)号：US20210401925A1
公开(公告)日：2021-12-30
申请号：US17233134
申请日：2021-04-16
发明人： D. Travis Wilson
摘要： The disclosure generally describes methods of preventing or treating dominant optic atrophy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates generally to the treatment or prevention of Leber's hereditary optic neuropathy (LHON) or dominant optic atrophy (DOA) in mammals through administration of therapeutically effective amounts of aromatic-cationic peptides to subjects in need thereof. In one aspect, the present disclosure provides a method of treating or preventing dominant optic atrophy in a mammalian subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide.
-
公开(公告)号：US20210154259A1
公开(公告)日：2021-05-27
申请号：US16919777
申请日：2020-07-02
发明人： Liping Liu , Shibo Tang , Xiaoling Liang
摘要： The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
-
公开(公告)号：US20210023160A1
公开(公告)日：2021-01-28
申请号：US16804900
申请日：2020-02-28
发明人： Kenneth Borow , D. Travis Wilson
摘要： This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31).
-
公开(公告)号：US20200376072A1
公开(公告)日：2020-12-03
申请号：US16994799
申请日：2020-08-17
发明人： D. Travis Wilson
IPC分类号： A61K38/07 , A61K31/165 , A61P29/00 , A61P27/02 , A61P13/12 , A61P9/12 , A61P7/06 , A61K45/06 , A61K38/18 , A61K38/13 , A61K38/06 , A61K31/737 , A61K31/727 , A61K31/192
摘要： The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
-
公开(公告)号：US10676506B2
公开(公告)日：2020-06-09
申请号：US16259575
申请日：2019-01-28
发明人： Scott M. Duncan
摘要： Disclosed are crystalline forms of the bis- and tris-(hydrochloride) salts of D-Arg-Tyr(2,6-DiMe)-Lys-Phe-NH2, which is also known as MTP-131.
-
公开(公告)号：US10576124B2
公开(公告)日：2020-03-03
申请号：US15313767
申请日：2015-05-27
发明人： D. Travis Wilson
IPC分类号： A61K38/10 , A61K38/06 , A61K38/08 , A61K38/07 , C07K5/078 , C07K5/09 , C07K5/087 , C07K5/107 , C07K5/065 , C07K5/113 , C07K5/072 , C07K5/097 , A61K47/64 , A61K38/05 , A61K38/13 , A61K38/17 , A61K38/40 , A61K38/44 , A61K38/45 , A61K38/46 , A61K38/51 , A61K38/53
摘要： Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2′,6′-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2′,6′-Dmt-Lys-Phe-NH2.
-
公开(公告)号：US20200017911A1
公开(公告)日：2020-01-16
申请号：US16101078
申请日：2018-08-10
发明人： D. Travis Wilson
IPC分类号： C12Q1/6883 , A61K38/06 , G01N33/92
摘要： The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and/or the presence or amount of enzymes involved in cardiolipin remodeling.
-
公开(公告)号：US20190233474A1
公开(公告)日：2019-08-01
申请号：US16259575
申请日：2019-01-28
发明人： Scott M. Duncan
摘要： Disclosed are crystalline forms of the bis- and tris-(hydrochloride) salts of D-Arg-Tyr(2,6-DiMe)-Lys-Phe-NH2, which is also known as MTP-131.
-
9.发明授权公开(公告)号：US10322159B2
公开(公告)日：2019-06-18
申请号：US15158005
申请日：2016-05-18
发明人： D. Travis Wilson , Kenneth Borow , Robert A. Kloner , Sharon Hale
摘要： The invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods provide administering aromatic-cationic peptides in effective amounts to prevent or treat an anatomic zone of no re-flow in mammalian subjects. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.
-
10.发明申请公开(公告)号：US20180360906A1
公开(公告)日：2018-12-20
申请号：US15873099
申请日：2018-01-17
发明人： D. Travis WILSON , Robert A. KLONER
IPC分类号： A61K38/06 , A61K45/06 , A61K38/07 , A61K31/401 , A61K31/573
摘要： The disclosure provides methods and compositions for increasing SERCA2a expression levels in a mammalian subject in need thereof. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide to subjects in need thereof. In some embodiments, the aromatic-cationic peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof such as acetate or trifluoroacetate salt. In some embodiments, the subject has suffered a myocardial infarction.
-
-
-
-
-
-
-
-
-
搜索结果
99 条记录 (耗时 0.034 秒)